You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,153,632


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,153,632 protect, and when does it expire?

Patent 8,153,632 protects VONJO and is included in one NDA.

This patent has forty-nine patent family members in twenty-one countries.

Summary for Patent: 8,153,632
Title:Oxygen linked pyrimidine derivatives
Abstract: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.
Inventor(s): Blanchard; Stephanie (Singapore, SG), Lee; Cheng Hsia Angeline (Singapore, SG), Nagaraj; Harish Kumar Mysore (Singapore, SG), Poulsen; Anders (Singapore, SG), Sun; Eric T. (Singapore, SG), Tan; Yee Ling Evelyn (Singapore, SG), William; Anthony Deodaunia (Singapore, SG)
Assignee: S*BIO Pte Ltd. (Singapore, SG)
Application Number:12/093,867
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Device;

Drugs Protected by US Patent 8,153,632

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cti Biopharma Corp VONJO pacritinib citrate CAPSULE;ORAL 208712-001 Feb 28, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2) ⤷  Try a Trial
Cti Biopharma Corp VONJO pacritinib citrate CAPSULE;ORAL 208712-001 Feb 28, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF MYELOFIBROSIS WITH PACRITINIB ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,153,632

PCT Information
PCT FiledNovember 15, 2006PCT Application Number:PCT/SG2006/000352
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/058627

International Family Members for US Patent 8,153,632

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria E469158 ⤷  Try a Trial
Australia 2006316071 ⤷  Try a Trial
Australia 2006316072 ⤷  Try a Trial
Brazil PI0618552 ⤷  Try a Trial
Canada 2629443 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.